BNET Industries
Market Cap:$322.6M
Last Fiscal Year Sales:$9.8M
- Public
- US
Dow Jones Description
We are a clinical-stage biopharmaceutical company committed to discovering and developing innovative therapies offering significant medical advances and new options for patients. We are focused on discovering, developing and commercializing oral drugs in four major therapeutic areas: cardiovascular, central nervous system, inflammatory and metabolic diseases. Our lead drug candidate, lorcaserin hydrochloride, or lorcaserin, is being investigated in a Phase 3 clinical trial program for the treatment of obesity. Our broad pipeline of novel compounds targets G protein-coupled receptors, or GPCRs, and includes compounds being evaluated independently and with partners, including Merck & Co., Inc., or Merck, and Ortho-McNeil-Janssen Pharmaceuticals, Inc., or Ortho-McNeil-Janssen. We focus on GPCRs because they are a validated class of drug targets that mediate the majority of cell-to-cell communication in humans. A high percentage of todays prescription drugs target one or more GPCRs, and we believe that approved GPCR-based drugs target only approximately one third of the known non-sensory GPCRs. Selective targeting of specific GPCRs is intended to increase the likelihood of the desired pharmacology and minimize the risk of off target effects. We believe our GPCR-focused technologies and integrated discovery and development capabilities will allow us to continue to build our pipeline of unique and selective drug candidates. ...
Co-Founder, Chairman, President and Chief Executive Officer
Jack LiefNumber of Employees 499
Contact Information
6166 Nancy Ridge Dr
San Diego, California 92121-3223
(858) 453-7200
Peer Companies
NAICS Code Pharmaceutical Preparation Manufacturing: 325412
Recent Events
-
Arena Pharmaceuticals, Inc. ARNA Announces Third Quarter 2009 Financial Results and Recent Developments
-
Morning Movers 9/15: LXRX, AMTY, DIET, DARA, BCRX Higher; ZOOM, NTWK, GRT, ARNA Lower
-
Rodman and Renshaw Downgrades Arena Pharma ARNA to Market Perform
-
Arena Pharmaceuticals Announces Second Quarter 2009 Financial Results and Recent Developments
News & Analysis
Filter by
arena pharmaceuticals inc. - All News and Analysis
Arena Pharmaceuticals Inc. Q3 2009 Earnings Call Transcript
Question-and-Answer SessionOperator Operator Instructions Your first question comes from Craig Gordon - Cohen & Co. Craig Gordon - Cohen & Co. A couple questions, in the NDA Submission, do you guys plan on submitting proposals both for Phase IV commitments as well as a REMS program? Bill Shanahan We...
Arena?s Lorcaserin Has Safety Edge
Zacks.com submits: Results from Arena’s ARNA phase III BLOSSOM study are strikingly similar to the BLOOM study, with mean total weight loss for the 10mg lorcaserin BID group coming in at 17.0 lbs in BLOSSOM vs. 17.9 lbs in BLOOM. These equated to 7.9% and 8.2% mean absolute...
Two Positive Notes for Arena Pharmaceuticals
Ruthanne Williams Roussel submits: Arena ARNA releases more top-line pivotal data on flagship obesity drug lorcaserin, this time from its BLOSSOM study Behavioral modification and Lorcaserin Second Study for Obesity Management Friday 9/18, before market open. Two things that could be great for ARNA: by Ruthanne Williams Roussel
Arena: Obesity Is a Large Market Opportunity
Zacks.com submits: Large Market Opportunity... In our view, obesity remains the single largest opportunity for a new pharmaceutical product today. Roughly two-thirds of the U.S. population is overweight. The number is expected to grow to 75% by 2015. There is massive unmet medical need and clear pharmacoeconomic benefits...
Arena Patients Keep Weight Off, Bodes Well for Partnership
Ruthanne Williams Roussel submits: Arena's big news at the American Diabetes Association meeting last weekend was that the analysis of the two-year pivotal Phase III BLOOM study data showed that patients were keeping off the weight they were losing on lorcaserin. This of course is terrific and bodes...
Arena's Prospects Will Be in the Eye of the Suitors
Derek Lowe submits: I’ve been getting a lot of objections to my opinion on Arena’s ARNA obesity candidate lorcaserin. Specifically, the first level of the dispute seems to be whether or not the recent clinical trial results met the FDA’s criteria for efficacy or not. So, let’s look at...
Arena Pharma Could Be on the Verge of Collapse
Derek Lowe submits: I wrote in March about locaserin, Arena Pharmaceutical's ARNA serotonin ligand for obesity. Their clinical data had come out, and things at least to me didn't look good. They didn't quite make the minimum threshold for efficacy, and the FDA isn't in a mood to take...
Arena's Obesity Drug Not Likely to Make It
Derek Lowe submits: One of the drug targets for obesity that’s been kicking around for years now is a serotonin-receptor based idea, a 5-HT2c agonist. There are several lines of evidence that make this a plausible way to affect appetite – well, as plausible as any of the appetite-based...
Arena's Financing Deal with Azimuth Is a Healthy Move
Mark Cifra submits: Secondaries and convertibles are pretty common stuff to most biotech investors. That is why when I first read the news that Arena Pharmaceuticals ARNA signed an equity financing commitment deal for 50 million dollars, I figured it was the same old biotech secondary. Until I caught the...
Arena Pharmaceuticals, Inc. Q4 2008 Earnings Call Transcript
Question-and-Answer Session Operator Operator Instructions. Our first question will come from Alan Carr with Needham. Alan Carr – Needham Could you clarify a bit your financial guidance for ’08? You said that your expenses for this year, you ended with 110, but I was wondering...
Those who viewed this also viewed...
Decision Makers
| Name (plus bio) | Position |
|---|---|
| Dominic P. Behan | Co-Founder, Director, Senior Vice President and Chief Scientific Officer |
| Robert E. Hoffman | Vice President, Finance and Chief Financial Officer |
| William Shanahan | Vice President & Chief Medical Officer |
| Steven Spector | Senior Vice President, General Counsel and Secretary |
| K. A. Ajit-Simh | Vice President, Quality Sys |
| K. Smith | Vice President, Quality Systems |
| Louis J. Xcotti | Vice President, Business Development & Marketing |
| Louis Scotti | Vice President, Marketing and Business Development |
| Derek Chalmers | Co-Founder |
| David Walsey | Director, Corporate Communications |
| J Clayburn La | |
| James E Flynn | |
| Clayburn Force | Director |
| Harry F. Hixson | Director |
| J. Clayburn La Force | Director |
| Tina S. Nova | Director |
| Donald D. Belcher | Member |
| Scott H. Bice | Member |
Board of Directors
| Name (plus bio) | Position |
|---|---|
| Jack Lief | Co-Founder, Chairman, President and Chief Executive Officer |
| Christine A. White | Board of Directors |
| Phillip M. Schneider | Board of Directors |
| Randall E Woods | Board of Directors |
| Robert L. Toms | Board of Directors |
| Tina Nova Bennett | Board of Directors |
Jack Lief is a co-founder of Arena and has served as a director and our President and Chief Executive Officer since April 1997. Mr. Lief has also served as the Chairman of our Board of Directors since October 2007. From 1995 to April 1997, Mr. Lief served as an advisor and consultant to numerous biopharmaceutical organizations. From 1989 to 1994, Mr. Lief served as Senior Vice President, Corporate Development and Secretary of Cephalon, Inc., a biopharmaceutical company. From 1983 to 1989, Mr. Lief served as Director of Business Development and Strategic Planning for Alpha Therapeutic Corporation, a manufacturer of biological products. Mr. Lief joined Abbott Laboratories, a pharmaceutical company, in 1972, where he served until 1983, most recently as the head of International Marketing Research. Mr. Lief serves as a member of the board of directors of Adventrx Pharmaceuticals, Inc., a research and development company focused on pharmaceuticals for cancer and infectious disease. Mr. Lief is also an Executive Board Member of BIOCOM, a life science industry association representing more than 550 member companies in Southern California, and was the Chairman of the board of directors of BIOCOM from March 2005 to March 2006. Mr. Lief holds a B.A. from Rutgers University and an M.S. in Psychology (Experimental and Neurobiology) from Lehigh University.
| Organization | Position | Status |
|---|---|---|
| Arena Pharmaceuticals, Inc. | Co-Founder, Chairman, President and Chief Executive Officer | Current |
| A-R-E-N-A.Com | Co-Founder | Current |
| Adventrx Pharmaceuticals Inc | Chairman | Current |
| Biocom, Inc. | Executive Board Member | Current |
| Southern California Inc | Board of Directors | Current |
| Cephalon, Inc. | Senior Vice President, Corporate Development | Former |
| Biocom, Inc. | Chairman | Former |
| Arena Pharmaceuticals, Inc. | Board of Directors | Former |
| Adventrx Pharmaceuticals Inc | Board of Directors | Former |
| Cephalon, Inc. | Secretary | Former |
| Rutgers University | B.A. | Former |
Dominic P. Behan, Ph.D., is a co-founder of Arena and has served as a director since April 2000, and as our Senior Vice President and Chief Scientific Officer since June 2004. Dr. Behan served as our Vice President, Research from April 1997 to June 2004. From 1993 to January 1997, Dr. Behan directed various research programs at Neurocrine Biosciences, Inc., a biopharmaceutical company. From 1990 to 1993, Dr. Behan was engaged in research at the Salk Institute. Dr. Behan holds a B.Sc. in Biochemistry from Leeds University, England, and a Ph.D. in Biochemistry from Reading University, England.
| Organization | Position | Status |
|---|---|---|
| Arena Pharmaceuticals, Inc. | Co-Founder, Director, Senior Vice President and Chief Scientific Officer | Current |
| A-R-E-N-A.Com | Co-Founder | Current |
| Arena Pharmaceuticals, Inc. | Director | Current |
| Salk Institute | Former | |
| Neurocrine Biosciences, Inc. | Former | |
| Reading University | Ph.D. In Biochemistry | Former |
| Leeds University | B.Sc. In Biochemistry | Former |
Robert E. Hoffman, C.P.A., has served as our Vice President, Finance and Chief Financial Officer since December 2005. Mr. Hoffman served as our Vice President, Finance and Chief Accounting Officer from June 2004 to December 2005, as our Vice President, Finance from April 2000 to June 2004, and as our Controller from August 1997 to April 2000. From 1994 to 1997, Mr. Hoffman served as Assistant Controller for Document Sciences Corporation, a software company. Mr. Hoffman serves as a member of the steering committee of the Association of Bioscience Financial Officers and as a supervisory committee member of the San Diego County Credit Union. He is also a director and a former President of the San Diego chapter of Financial Executives International. Mr. Hoffman holds a B.B.A. from St. Bonaventure University and is licensed as a C.P.A. in the State of California.
| Organization | Position | Status |
|---|---|---|
| Arena Pharmaceuticals, Inc. | Vice President, Finance and Chief Financial Officer | Current |
| Arena Pharmaceuticals, Inc. | Board of Directors | Current |
| Document Sciences Corporation | Assistant Controller | Former |
| St. Bonaventure University | B.B.A. | Former |
William R. Shanahan, Jr., M.D., J.D., has served as our Vice President and Chief Medical Officer since March 2004. From August 2000 to March 2004, Dr. Shanahan served as Chief Medical Officer for Tanox, Inc., a biopharmaceutical company. From October 1994 to August 2000, Dr. Shanahan held various positions at Isis Pharmaceuticals, Inc., a biopharmaceutical company, most recently as Vice President, Drug Development. From 1989 to 1994, Dr. Shanahan served as Director, Clinical Research for Pfizer Central Research, a pharmaceutical company. From 1986 to 1989, Dr. Shanahan held various positions at Searle Research & Development, a pharmaceutical company subsequently acquired by Pfizer, most recently as Director, Clinical Research. Dr. Shanahan holds an A.B. from Dartmouth College, an M.D. from the University of California, San Francisco and a J.D. from Loyola University, Chicago.
| Organization | Position | Status |
|---|---|---|
| Arena Pharmaceuticals, Inc. | Vice President & Chief Medical Officer | Current |
| Merchant Advisory Group (Mag) | Board of Directors | Current |
| Olink | Board of Directors | Current |
| Industry Ventures | Board of Directors | Current |
| IDEXX Laboratories, Inc. | Board of Directors | Current |
| Diageo plc | Board of Directors | Current |
| Resgen Inc. | Board of Directors | Current |
| Pittsburgh Tissue Engineering Initiative, Inc | Board of Directors | Current |
| Microseq | Board of Directors | Current |
| Merchant Advisory Group (Mag) | Committee Member | Current |
| Colgate-Palmolive Company | President | Former |
| Tanox, Inc. | Chief Medical Officer | Former |
| Isis Pharmaceuticals, Inc. | Vice President | Former |
| Pfizer Inc. | Director | Former |
| The University of California, San Francisco | M.D. | Former |
| Loyola University | J.D. | Former |
| University of California, San Francisco | M.D. | Former |
| Dartmouth College | Bachelor of Arts Degree In Geography | Former |
Steven W. Spector, J.D., has served as our Senior Vice President and General Counsel since June 2004. Mr. Spector served as our Vice President and General Counsel from October 2001 to June 2004. Mr. Spector has also served as our Secretary since November 2001. Mr. Spector is a member of the board of directors and the immediate-past President of the Association of Corporate Counsel, San Diego. Prior to joining Arena, Mr. Spector was a partner with the law firm of Morgan, Lewis & Bockius LLP, where he worked from 1991 to October 2001. Mr. Spector was a member of the Morgan Lewis Technology Steering Committee. Mr. Spector was our outside corporate counsel from 1998 to October 2001. Mr. Spector holds a B.A. and a J.D. from the University of Pennsylvania.
| Organization | Position | Status |
|---|---|---|
| Arena Pharmaceuticals, Inc. | Senior Vice President, General Counsel and Secretary | Current |
| A-R-E-N-A.Com | Current | |
| Arena Pharmaceuticals, Inc. | Secretary | Current |
| Chemnavigator.Com, Inc. | Director | Former |
| University of Pennsylvania | B.A. and A J.D. | Former |
K.A. Ajit-Simh has served as our Vice President, Quality Systems since January 2004. Mr. Ajit-Simh provided regulatory compliance services to several companies in the United States and internationally from 1999 to the end of 2003. Mr. Ajit-Simh held various positions of increasing responsibility at Mallinckrodt Inc. from 1975 to 1985, Baxter Healthcare from 1986 to 1989, Abbott BioTech from 1989 to 1992, and Cytel Corporation from 1992 to 1999. In addition, he has been an instructor at the University of California, San Diego since 1994, teaching classes in regulatory compliance and quality control/assurance. He also teaches courses in Good Manufacturing Practices and Advanced Quality Control and Assurance at San Diego State University as part of the graduate program in Regulatory Affairs. Mr. Ajit-Simh received a B.Sc. degree in Biology and Chemistry from Bangalore University and an M.S. in Cell Biology from St. Louis University.
| Organization | Position | Status |
|---|---|---|
| Arena Pharmaceuticals, Inc. | Vice President, Quality Sys | Current |
| Organization | Position | Status |
|---|---|---|
| Arena Pharmaceuticals, Inc. | Vice President, Quality Systems | Current |
| Organization | Position | Status |
|---|---|---|
| Arena Pharmaceuticals, Inc. | Vice President, Business Development & Marketing | Current |
| Organization | Position | Status |
|---|---|---|
| Arena Pharmaceuticals, Inc. | Vice President, Marketing and Business Development | Current |
| Ligand Pharmaceuticals Incorporated | Executive Director | Former |
| University of Pennsylvania | B.S.E. In Biomedical Engineering | Former |
| Organization | Position | Status |
|---|---|---|
| Cara Therapeutics Inc. | Chief Executive Officer, President, and Director | Current |
| Arena Pharmaceuticals, Inc. | Co-Founder | Current |
| Cara Therapeutics Inc. | Co-Founder | Current |
| Cara Therapeutics Inc. | Board of Directors | Current |
| A-R-E-N-A.Com | Vice President | Former |
| A-R-E-N-A.Com | Executive Director | Former |
| Neurocrine Biosciences, Inc. | Principal Investigator | Former |
| Organization | Position | Status |
|---|---|---|
| Arena Pharmaceuticals, Inc. | Director, Corporate Communications | Current |
| Arena Pharmaceuticals, Inc. | Board of Directors | Current |
| Organization | Position | Status |
|---|---|---|
| Arena Pharmaceuticals, Inc. | Current | |
| University of California, Los Angeles | professor of Economics | Former |
| Micromet, Inc. | member | Former |
| University of California, Los Angeles | Chairman | Former |
| University of California, Los Angeles | Ph.D. in Economics | Former |
| Organization | Position | Status |
|---|---|---|
| Arena Pharmaceuticals, Inc. | Current |
| Organization | Position | Status |
|---|---|---|
| Novarx Corporation | Member of the Novarx Scientific Advisory Board | Current |
| Arena Pharmaceuticals, Inc. | Board of Directors | Current |
| Arena Pharmaceuticals, Inc. | Member | Current |
| Sidney Kimmel Cancer Center | Director of Clinical Oncology Research | Former |
| Biogen Idec, Inc. | Former | |
| Department of Medicine | Chair | Former |
| Sidney Kimmel Cancer Center | Chairman | Former |
| University of Chicago | M.D. | Former |
| University of Chicago | B.A In Biology | Former |
| University of Chicago | Degree | Former |
| Organization | Position | Status |
|---|---|---|
| Arena Pharmaceuticals, Inc. | Director | Current |
Array
| Organization | Position | Status |
|---|---|---|
| Sequenom, Inc. | Chairman of the Board of Directors | Current |
| San Diego Opera | Member of the Board | Current |
| Discovery Partners International, Inc. | Board of Directors | Current |
| Signal Pharmaceuticals, LLC | Director | Current |
| Arena Pharmaceuticals, Inc. | Director | Current |
| Infinity Pharmaceuticals, Inc | Director | Current |
| Arena Pharmaceuticals, Inc. | Member | Current |
| Braincells, Inc. | Chief Executive Officer | Former |
| Amgen Inc. | President and Chief Operating Officer and Member | Former |
| Braincells, Inc. | Co-Founder | Former |
| Abbott Laboratories | Former | |
| Discovery Partners International, Inc. | Chairman | Former |
| Sequenom, Inc. | Board of Directors | Current |
| University of Chicago | M.B.A. | Former |
| Purdue University | B.S. In Chemical Engineering | Former |
| Amgen Inc. | Member | Former |
J. Clayburn La Force, Jr., Ph.D., has served as a member of our Board of Directors since October 2002. Dr. La Force served as a professor of Economics at the University of California, Los Angeles from 1962 to 1978, and served as Dean of the Anderson School of Management at the University of California, Los Angeles from July 1978 to June 1993. From 1969 to 1978, Dr. La Force served as the Chairman of the Economics Department at the University of California, Los Angeles. Dr. La Force formerly severed on a number of boards of directors, including for the following registered investment companies: Payden Funds, Metzler Payden, and Advisors Series Trust. Dr. La Force holds an A.B. in Economics from San Diego State College and an M.A. and a Ph.D. in Economics from the University of California, Los Angeles.
| Organization | Position | Status |
|---|---|---|
| Arena Pharmaceuticals, Inc. | Director | Current |
| University of California, Los Angeles | Professor | Former |
| University of California, Los Angeles | Ph.D. In Economics | Former |
| University of California | PH.D. In Economics | Former |
| University of California, Los Angeles | M.A. In Economics | Former |
| University of California | M.A. | Former |
| University of California | A.B. In Economics | Former |
| Organization | Position | Status |
|---|---|---|
| Targegen, Inc. | Board of Directors | Current |
| Arena Pharmaceuticals, Inc. | Board of Directors | Current |
| Gen-Probe Inc. | Board of Directors | Current |
| Mlt Research Limited | Director | Current |
| Micromet, Inc. | Board of Directors | Current |
| Idec Pharmaceuticals Corporation | Chief Financial Officer | Former |
| Idec Pharmaceuticals Corporation | Senior Vice President | Former |
| Gen-Probe Inc. | Chair | Former |
| University of Southern California | M.B.A. | Former |
| University of Southern California | M.B.A. | Former |
| University of California | B.S. In Biochemistry | Former |
| University of California, Davis | B.S. In Biochemistry | Former |
| Organization | Position | Status |
|---|---|---|
| Novacardia, Inc | President and Chief Executive Officer | Current |
| Sequel Pharmaceuticals, Inc. | President and CEO | Current |
| Bente Hansen & Associates | President | Current |
| Biocom, Inc. | Chairman of The Board of Directors | Current |
| Sequel Pharmaceuticals, Inc. | Member of The Board of Directors | Current |
| Bente Hansen & Associates | Board of Directors | Current |
| Arena Pharmaceuticals, Inc. | Board of Directors | Current |
| Novacardia, Inc | Board of Directors | Current |
| Corvas International, Inc. | Chief Executive Officer | Former |
| NovaCardia, Inc. | Chief Executive Officer | Former |
| NovaCardia, Inc. | President | Former |
| Boehringer Mannheim | Vice President of Marketing and Sales | Former |
| Eli Lilly and Company | Former | |
| Sequel | Former | |
| Biocom, Inc. | Board of Directors | Former |
| Western Michigan University | M.B.A. | Former |
| Ball State University | B.S. Degree In Biology | Former |
| Organization | Position | Status |
|---|---|---|
| Arena Pharmaceuticals, Inc. | Board of Directors | Current |
| Organization | Position | Status |
|---|---|---|
| Arena Pharmaceuticals, Inc. | Board of Directors | Current |
| Selective Genetics | Chief Operating Officer | Former |
| Nanogen, Inc. | Co-Founder | Former |
| Hybritech, Inc. | Former | |
| University of California, Irvine | B.S. In Biological Sciences | Former |
Timothy M. Buono has served on our board of directors since March 2000. Mr. Buono is a founder and member of Aura Equity Partners, LLC, a private equity firm focused on growth oriented investments in companies within the consumer driven health and personal care markets. Mr. Buono previously served as vice-president of Tullis-Dickerson & Co., Inc. from 1997 to 2008, a healthcare focused venture capital firm. During this time, he was also a partner in the general partner entities of its sponsored venture capital funds. From 1994 to 1997, he served as senior vice president, business development, for Health Partners, Inc., a healthcare services company. From 1993 to 1994, Mr. Buono served as director, business development, for Occupational Health Resources, Inc., a healthcare services company. From 1990 to 1993, Mr. Buono served as an associate of Tullis-Dickerson & Co., Inc. From 1988 to 1990, Mr. Buono was a financial and operations analyst for Shaffer-Clarke. Mr. Buono is a director of a number of privately-held companies. He received his B.A. in Economics from Connecticut College in 1988, and completed an Executive Program at Columbia University’s Graduate School of Business in 2003.
| Organization | Position | Status |
|---|---|---|
| Genoptix, Inc. | President, Chief Executive Officer | Current |
| University of San Diego | Board of Directors | Current |
| UCSD-CONNECT | Director | Current |
| Cyntellect, Inc. | Member of the Company's Board of Directors | Current |
| Cypress Bioscience, Inc. | Board of Directors | Current |
| Heska Corporation | Director | Current |
| Biocom, Inc. | Executive Board Member | Current |
| Arena Pharmaceuticals, Inc. | Director | Current |
| Arena Pharmaceuticals, Inc. | Member | Current |
| Nanogen, Inc. | Chief Operating Officer and President | Former |
| Selective Genetics | Chief Operating Officer | Former |
| Ligand Pharmaceuticals Incorporated | Executive Director | Former |
| Nanogen, Inc. | Co-Founder | Former |
| Genoptix, Inc. | Co-Founder | Former |
| Hybritech, Inc. | Former | |
| University of California | PH.D. In Biochemistry | Former |
| University of California, Riverside | Ph.D. Degree In Biochemistry | Former |
| University of California, Irvine | B.S. In Biological Sciences | Former |
| Cyntellect, Inc. | Member | Former |
| Heska Corporation | member | Former |
Mr. Belcher has served as a member of our Board of Directors since December 2003. Mr. Belcher served as Chairman of the Board of Directors of Banta Corporation, a printing and supply-chain management company, from May 1995 to April 2004, Chief Executive Officer from January 1995 to October 2002 and President from September 1994 to January 2001. Mr. Belcher holds a B.A. from Dartmouth College and an M.B.A. from the Stanford University Graduate School of Business.
| Organization | Position | Status |
|---|---|---|
| Arena Pharmaceuticals, Inc. | Member | Current |
| Arena Pharmaceuticals, Inc. | Director | Current |
| Banta Corporation | Chairman of the Board of Directors | Former |
| Stanford University | M.B.A. | Former |
| Dartmouth College | B.A. | Former |
Scott H. Bice has served as a member of our Board of Directors since December 2003. Since June 2000, Mr. Bice has been the Robert C. Packard Professor at the University of Southern California Law School, where he served as Dean from 1980 to June 2000. Mr. Bice has experience on several corporate boards, including Imagine Films, from 1992 to 1994, Western and Residence Mutual Insurance Companies, from 1996 to 2003, and Jenny Craig, from 1996 to 2002. Mr. Bice holds a B.S. in finance and a J.D. from the University of Southern California.
| Organization | Position | Status |
|---|---|---|
| Arena Pharmaceuticals, Inc. | Member | Current |
| Arena Pharmaceuticals, Inc. | Director | Current |
| University of Southern California School of Law | Professor | Former |
| University of Southern California | J.D. | Former |
Executive News
-
Genoptix: Adding Physicians, Growing Revenue
Industry Transcripts by Seeking Alpha
-
Palatin Technologies F1Q10 (Qtr End 9/30/09) Earnings Call Transcript
on Nov 16, 2009about PTN
-
Flamel Technologies SA Q3 2009 Earnings Call Transcript
on Nov 16, 2009about FLML
-
NexMed Inc. Q3 2009 Earnings Call Transcript
on Nov 10, 2009about NEXM
-
InterMune, Inc. Q3 2009 Earnings Call Transcript
on Nov 10, 2009about ITMN
-
Arena Pharmaceuticals Inc. Q3 2009 Earnings Call Transcript
on Nov 10, 2009about ARNA
IndustryTop Rated
- How NOT to Write a Biotech Press Release: Just Ask Epeius 5 votes
- The 10 Weirdest Drug Stories of the Month 3 votes
- More Tysabri Problems; Time for a Biogen-Idec Credibility Check 3 votes
- Fired Whistleblower Reps Make Similar Claim: Pfizer Said They Lacked "Integrity" 3 votes
- VeriChip TV Ad Confirms Critics' Fears: They Want Everyone Implanted 3 votes

